Fig. 2.

Retardation of tumor growth in BALB-neuT mice by in vivo inhibition of IL-13 activity. BALB-neuT mice (5/group) were treated with IL-13 inhibitor, sIL-13Rα2-Fc, (0.2 mg/injection) every other day for the first 2 weeks starting from the age of 4–5 weeks (two independent experiments in panels a and b) or from the age of 8–10 weeks (panel c), then twice weekly until 21 weeks. The control group was treated with control isotype-matched human IgG. Left panels mean tumor incidence/mouse; right panels cumulative tumor incidence/group (independent tumors in 50 mammary glands per group)